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Introduction. Procalcitonin (PCT) is a biomarker of systemic infection. Specificity of PCT
is decreased because PCT is also elevated after heart transplantation (HTx). There is no
established normal range of serum PCT concentrations after HTx yet.
Our aim was to determine the course of PCT concentrations in patients after HTx in the
early postoperative period, if we can discriminate postoperative increase in values from
infectious complications.
Results. Of 39 patients we diagnosed infection in 11. These patients develop acute kidney
injury significantly more often than in control group (group C) (5 in infection group [group
I] and 2 in group C, P < .05), and 1 patient died within 30 days in group C. Seven patients
developed primary graft dysfunction (3/4 þ ECMO [extracorporeal membrane oxygena-
tion], respectively, group I/group C) and 2 neurologic disorders in group I. Reoperation
due to bleeding was 3 in each group. During the 14 days after HTx, serum PCT concen-
trations increased with maximum on the second postoperative day (group C: 30.6  15.3
ng/mL; group I: 24.9  44.3 ng/mL). Normal values for PCT were reached on day 8 in
group C and 11 in group I. Mean PCT levels were similar: 8.7  5.7 ng/mL vs 11.9  13.1
ng/mL in group I vs group C, respectively. Patients in group I stayed longer in the intensive
care unit.
Conclusions. Despite increase in serum concentration of PCT in early postoperative course
afterHTx there is nomarker of infection. Trends in PCT serumconcentrationmay be a valuable
tool in diagnosis of infection in patients after HTx, but further investigation is needed.*Address correspondence to Marek Grochla, ul. M.Curie-
Skłodowskiej 9, 41-800 Zabrze, Poland. Tel/Fax:þ48322732731.
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in the C cells of the thyroid gland and K cells of the lung
[1,2]. In healthy subjects, PCT levels are usually below the
detection threshold [3]. Several reports show the superiority
of PCT over other biomarkers in diagnosing systemic
infection either in normal or immunocompromised pop-
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Table 1. Demographic Data and Comorbidities
With Infection Without Infection P
Age, y 52  7.2 47.6.4  10.5 .22
Hypertension 3 (27%) 6 (21%) .32
Diabetes mellitus 7 (64%) 19 (68%) .12
Ischemic cardiomyopathy 3 (27%) 7 (25%) .21
Nonischemic cardiomyopathy 8(73%) 21(75%) .42
Renal impairment 4 (36%) 5 (18%) .74
Neurological disorders 2 (18%) 5 (18%) .26
Sex, male 10 (91%) 21 (81%) .048
Table 2. Results
With Infection Without Infection P
Procalcitonin (ng/mL) 8.75.7 11.913.1 .44
Death in 30 days, n 0 1 (4%) .16
Primary graft dysfunction, n 2 (20%) 5 (26%)
(1 ECMO)
.52
Reoperation, n 3 (27%) 3 (20%) .53
Neurologic disorders 2 (20%) 0 .16
ICU stay (d) 2419 117 .004
Abbreviations: ECMO, extracorporeal membrane oxygenation; ICU, intensive
care unit.
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necessitate early identification, timely therapeutic inter-
vention, and urgent treatment [1e4]. Unfortunately, the
specificity of PCT in predicting a bacterial complication has
been decreased by the fact that PCT is also elevated after
major surgery where bacterial infection is ruled out. How-
ever, monitoring the postoperative course, even if PCT
values are elevated, does not limit the utility of PCT as a
diagnostic tool [5]. The investigators therefore think that a
reference range of every type of surgery should be estab-
lished. As a consequence, PCT kinetics and its nonspecific
increase during the following first few days will help to
monitor patients at risk [6]. According to Mandershahian
and colleagues there is no established normal range of
serum PCT concentrations after heart transplantation
(HTx) yet. We do not know which cut-off value can be a
discriminating parameter for infectious complications [5].
The aim of our study was to determine course of PCT
concentrations in patients after heart transplantation in the
early postoperative period, if we can discriminate post-
operative increase in values from infectious complications.
MATERIAL AND METHODS
We retrospectively analyzed 41 consecutive adult orthotopic HTx
performed in Silesian Centre for Heart Disease in 2017. Patients
who died within 48 hours after grafting (n ¼ 2) were excluded from
the study. Of the 39 heart transplant recipients, 11 (10M/1F) in
group I had infection in the post-transplant period and 28 (23M/5F)
in group C without infection. The reason for heart failure were
ischemic cardiomyopathy in 3 patients in group I and 7 in group C.
Eight patients in group I and 21 in group C had nonischemic car-
diomyopathy. Additionally 4 patients in group I and 5 in group C
had diagnosed renal impairment, 7 had diabetes mellitus in group I
and 19 in group C, before transplantation. Infections were diag-
nosed according to clinical signs and confirmed by biological cul-
tures. PCT plasma levels were measured once daily, and we
analyzed up to 14 days of stay. Patients in group I were more often
males. Demographic data are collected in Table 1. The institutional
research ethics board reviewed and approved the study. Individual
resignation for consent was granted.
Data Collection
Patient demographics, comorbidities, and complications were
retrospectively analyzed using our institutional database and from
the medical records. Baseline information was collected before
orthotopic heart transplant. Patient demographic information andcomorbidities including age, sex, diabetes, etiology of cardiomyop-
athy, indication for transplantation, height, and weight were also
collected in order to calculate body mass index. We also collected
number of neurologic, pulmonary, infectious complications, renal
insufficiency, incidents of reoperations due to bleeding or tampo-
nade, days of mechanical ventilation, and duration of intensive care
unit (ICU) stay
Statistical Analysis
Data were analyzed using Statistica statistical software (StatSoft,
Tulsa, Okla, United States). Categorical variables were treated as
proportions, and continuous variables were reported as means and
standard deviations. We compared the groups using independent-
sample t tests for continuous variables and c2 and Fisher exact
tests for categorical data. Complications during LVAD support
were reported as event rates. A two-sided P value < .05 was
considered as statistically significant.RESULTS
Of 39 patients we diagnosed incidence of infections in 11 in
postoperative course. These patients developed acute kidney
injury significantly more often than in group C (5 in group I
and 2 in group C, P < .05); 1 patient died within 30 days in
group C. We noticed 7 patients with the use of intra-aortic
counter pulsation and one on extracorporeal membrane
oxygenation (ECMO) support (3/4 þ ECMO, respectively,
group I/group C) due to primary graft dysfunction and 2
neurologic disorders in group I. Reoperation due to bleeding
was 3 in group I and 3 in group C. PCT kinetics during the 14
days after HTx had fluctuation. Serum PCT concentrations
increased with maximum concentrations on the second post-
operative day (group C: 30.6  15.3 ng/mL; group I: 24.9 
44.3 ng/mL). From day 2, the levels of PCT decreased to
reach a level of normal values for PCT on day 8 in group C
and 11 in group I. Mean PCT levels were insignificantly
different and were 8.7  5.7 ng/mL vs 11.9  13.1 ng/mL in
group I vs group C, respectively. Patients in group I stayed
longer in the ICU. Results are collected in Table 2 and Fig 1.DISCUSSION
We retrospectively analyzed PCT plasma levels in patients
in the early postoperative period after HTx in our study.
There was no significant difference in PCT concentrations
between groups with and without infectious complications.
Fig 1. Daily PCT serum levels in
patients with uncomplicated (n ¼
28) and complicated (n ¼ 11)
postoperative course. Day 1 ¼
day of transplantation. Data are
given as mean. The bars indicate
0.95 confidence interval. Serum
PCT concentrations did not differ
significantly between patients
with and without complications.
PROCALCITONIN KINETICS AFTER HEART TRANSPLANT 2089High serum PCT levels are frequently seen after different
types of surgery or transplant procedures due tomany factors,
such a surgical trauma, myocardial ischemia, translocation of
bacterial endotoxins, high doses of catecholamines, or car-
diopulmonary bypass. Early postoperative period is often
associated with an inflammatory response and massive cyto-
kine cascade activation, thus PCT can be elevated in the
absence of bacterial infection [1e4].
PCT kinetics in recipients of organ transplants may be
influenced by several factors, including surgery, the presence
of underlying end organ disease, persistent immunosuppres-
sion, and type of immunosuppressive agents. This makes it
more difficult to interpret than in nontransplant patients [7e9].
In heart and lung transplantation, PCT levels were high
during the first day (usually 24-48 h) after surgical procedure
and remained elevated during the subsequent days in patients
with infection [5,6,10]. Madershahian et al showed in one
study that PCT levels increased on the second day after
surgery to 54.6  8.8 ng/mL in patients with complications,
compared with 9.1  9.3 ng/mL in patients without compli-
cations; 75% of patients on the seventh day after surgery with
no complicated course had a normal PCT value, whereas only
4% of patients with infectious and noninfectious complica-
tions had detection levels below the threshold [5]. Suberviola
et al found that after lung transplantation in patients who did
not receive induction therapy, PCT plasma levels reached
their peak within the first 48 hours and stabilized in the first
7 days after transplantation [6].PCT is a valuable biomarker for the identification of in-
fectious complications, with a sensitivity of 77% and a
specificity of 79% in meta-analysis by Wacker et al [11].
Guidelines recommend the cautious use of PCT with
regard to clinical and other laboratory data [12]. Patients
after transplantation should receive immunosuppressive
therapy according to protocols, which may result in
increased PCT concentrations.
There are several reports on extensively high PCT levels
in kidney transplant patients after T-cell antibody infusion
with no evidence of infection. Zazula et al showed that PCT
levels increased without any signs of infection in patients
undergoing orthotopic liver transplantation with anti-
thymocyte globulin (ATG) administration [13]. Similar re-
sults were shown by Brodska et al and Sabat et al [14,15].
Franekova et all reported that PCT was able to differ-
entiate between patients with and without septic complica-
tions in the early post-transplant period, but the
administration of ATG significantly affects the level of PCT
and may lead to difficulty in interpreting the results. Fra-
nekova et al described that presepsin is independent of
ATG administration and was significantly higher in infected
patients after HTx, thus, presepsin, not PCT, seems to be a
valuable biomarker for the detection of infectious compli-
cations after HTx [16]. Madershahian et al also suggested
that perioperative administration of immunosuppressive
therapy is associated with significantly increased PCT levels,
even in patients without infectious complications [17].
2090 NADZIAKIEWICZ, GROCHLA, KRAUCHUK ET ALOur study has a limitation of the statistical analysis due to
the low number of the patients. The results have to be
confirmed in larger studies.CONCLUSIONS
Despite increase in serum concentration of PCT in early
postoperative course after heart transplantation, there is no
marker of infection. Trends in PCT serum concentration
may be a valuable tool in diagnosis of infection in patients
after HTx, but further investigation is needed.REFERENCES
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